ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,048.42
-0.46%
US Tech 100
17,162.80
0.60%
Dow Jones
38,085.80
-0.98%
Brent Oil
88.145
-0.01%
Bitcoin
64,308.79
-0.27%
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Castle Biosciences Inc (CSTL) Quote

Castle Biosciences Inc

Castle Biosciences Inc (CSTL)

NASDAQ
19.51
-0.35
(-1.76%)
Closed April 26 4:00PM
Delayed by 15 minutes
19.51
0.00
(0.00%)
After Hours: 5:30PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
19.51
Bid
14.80
Ask
22.50
Volume
185,912
18.76 Day's Range 19.70
9.2601 52 Week Range 26.70
Market Cap
535.549M
Previous Close
19.86
Open
19.16
Last Trade
1078
@
19.51
(formt)
Last Trade Time
Financial Volume
$ 3,599,950
VWAP
19.3637
Average Volume (3m)
230,585
Shares Outstanding
27,449,983
Dividend Yield
-
PE Ratio
-9.32
Earnings Per Share (EPS)
-2.09
Revenue
219.79M
Net Profit
-57.47M

About Castle Biosciences Inc

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanom... Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Website
www.castlebiosciences.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Castle Biosciences Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker CSTL. The last closing price for Castle Biosciences was $19.86. Over the last year, Castle Biosciences shares have traded in a share price range of $ 9.2601 to $ 26.70.

Castle Biosciences currently has 27,449,983 shares outstanding. The market capitalization of Castle Biosciences is $535.55 million. Castle Biosciences has a price to earnings ratio (PE ratio) of -9.32.

CSTL Latest News

More News

Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first...

April 11 2024
Business Wire

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Esophageal Cancer Awareness Month and is...

April 10 2024
Business Wire

Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that, for the second year in a row, its chief financial...

April 10 2024
Business Wire

Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

If choosing to use a molecular test to rule-out a sentinel lymph node biopsy (SLNB) in patients diagnosed with melanoma, it is important to show that patients foregoing an SLNB have low risk...

April 04 2024
Business Wire

Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to...

April 02 2024
Business Wire

Castle Biosciences Announces Updates to its Board of Directors

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Rodney Cotton has been appointed to its board of...

March 27 2024
Business Wire

Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year

Company honored for creating an exceptional, people-first culture that empowers employees and fosters trust, transparency and authenticity Castle Biosciences, Inc. (Nasdaq: CSTL), a company...

March 25 2024
Business Wire

Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB

Castle’s second presentation at SSO 2024 shows that in a study of 979 patients, DecisionDx-Melanoma demonstrated clinical use value in patients with TI cutaneous melanoma (CM), identifying...

March 22 2024
Business Wire

Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy

The consensus guidelines were drafted by a multidisciplinary panel of radiation oncologists and dermatologists/Mohs micrographic surgeons with expertise in cutaneous squamous cell carcinoma (SCC...

March 19 2024
Business Wire

New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older

Study data show that one-third of the IDgenetix-guided medication recommendations were due to drug-drug interactions and lifestyle factors, demonstrating the value of this additional information...

March 15 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.673.5562632696418.8420.6718.513522819.64179412CS
4-1.86-8.7037903603221.3722.6718.515149120.73653983CS
12-3.71-15.977605512523.2225.617.4223058521.56830958CS
266.3848.591012947413.1325.612.2324446520.30154309CS
52-3.87-16.552609067623.3826.79.260138741717.84256435CS
156-48.61-71.35936582568.1278.929.260128102328.78844174CS
260-0.49-2.4520107.699.260125302134.54792571CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ISUNiSun Inc
$ 0.173
(84.04%)
19.93M
BRFHBarfresh Food Group Inc
$ 1.75
(69.90%)
44.33M
SGBXSafe and Green Holdings Corporation
$ 0.225
(56.14%)
136.91M
PCSAProcessa Pharmaceuticals Inc
$ 2.4137
(48.99%)
77.21M
BACKIMAC Holdings Inc
$ 5.065
(45.34%)
8.49M
EJHE Home Household Service Holdings Ltd
$ 0.767
(-73.64%)
12.36M
TVGNTevogen Bio Holdings Inc
$ 0.9057
(-39.62%)
328.69k
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.265
(-37.69%)
16.75M
ATNIATN International Inc
$ 19.24
(-33.01%)
440.2k
BNAIBrand Engagement Network Inc
$ 2.59
(-30.56%)
234.29k
SQQQProShares UltraPro Short QQQ
$ 12.00
(1.61%)
167.48M
SGBXSafe and Green Holdings Corporation
$ 0.225
(56.14%)
136.91M
TSLATesla Inc
$ 170.18
(4.97%)
126.42M
ACONAclarion Inc
$ 0.383149
(33.04%)
115.53M
TQQQProShares UltraPro QQQ
$ 52.85
(-1.60%)
86.41M

Discussion

View Full Feed
Truth and Transparency Truth and Transparency 3 minutes ago
I swear, you are the king of the DMF
NB
Susie924 Susie924 4 minutes ago
https://x.com/AdamParkhomenko/status/1783696134210224517
AlwaysOptimistic AlwaysOptimistic 5 minutes ago
That's an inaccurate statement, I have been to every available Town Hall meeting since 2013. To my knowledge, there have only been 4 Town Hall meetings not 11. Also, I provided why I do not believe they would do another Town Hall meeting now in a previous post. They are expensive and we are probably
NB
janice shell janice shell 7 minutes ago
When did you start believing that manipulating children was OK?

Most people believe it's okay. Can't have them growing up as little savages, can we? And oh my! The religious indoctrination!
G-OiL-D G-OiL-D 7 minutes ago
H2 here to stay.
https://www.msn.com/en-us/autos/news/everything-we-know-about-honda-s-new-hydrogen-vehicle/vi-AA1nrkuJ?ocid=mailsignout&pc=U591&cvid=44d17616c6604eeb826d84ca5e0b5baa&ei=413
HYZN
newflow newflow 7 minutes ago
NON BANK SUBS WERE TO RECEIVE NOTE RECEIVABLE FROM JPMC AS PER DISCLOSURE STATEMENT
Of WMI’s seven remaining Non-Banking Subsidiaries, WMMRC, which is currently operating on a run-off basis, WMMRC is the only Non-Banking Subsidiary with ongoing operations. Refer to Articles IV.A.6, VII, and
JPM
SeekTruthAlways SeekTruthAlways 10 minutes ago
HOLCOMB LOSES BANKRUPTCY STAY OF ENFORCEMENT OF RECORDED JUDGEMENT
BANKRUPTCY PROCEEDS AGAINST HOLCOMB $35M + INTEREST
https://drive.google.com/file/d/1TNLzrz30Zrq6fFVmFWAwDkRZryidSKin/view
ASRE
littlejohn littlejohn 11 minutes ago
SMCI has gap at $496 on 01/29/24

to heed for potential retrace

to fill it...

SMCI has bounced around $300

on days so could still fill the gap

before ER on Tuesday...

https://www.barchart.com/stocks/quotes/SMCI/
AMD CPE NVDA
newflow newflow 11 minutes ago
No problem Split T, we could see the light one day with a new ticker with steady dividends IMO.
COOP
Truth and Transparency Truth and Transparency 11 minutes ago
NO, I mean 1,000. There has been two reverse splits with the first GX SPAC that they (Kepler/Bloom) had with Celularity. It’s not very complicated math.

Here’s the math:

100,000/10 = 10,000
10,000/10 = 1,000

If we drop below $1.00 like Celularity d
NB
iHubInvestor70 iHubInvestor70 12 minutes ago
2,500,000 shares issued to the daughter of the Company’s CEO....From the Q "On January 1, 2024, the company Board of Directors approved and issued 5,000,000 shares of common stock in connection with employee compensation. Included in the issuance are 2,500,000 shares issued to the daughter of the Co
RTON
Doc logic Doc logic 12 minutes ago
georgebailey,

…and Edens works with both DCs and T-cells. Talk about being prepared with advanced commercialization of improved product line; ). Best wishes.
NWBO
weedtrader420 weedtrader420 12 minutes ago
SHIBA FERRARI welcome to the machine
SHIBUSD
Saving Grace Saving Grace 15 minutes ago
Yes, with CBD products on Amazon. ERBB wins and wins big.

ERBB revenue doubled in 2023. 2024 will be exciting times.

ERBB is going to turn this up a notch. Pay Attention!
ERBB
hssbwwmp hssbwwmp 15 minutes ago
Will SBFM be on the Nasdaq delisting list soon? They aren't on the list as of April 25th (see link) but looks like the have failed miserably to meet the listing requirements, and burned a lot of investors by this failure.

https://listingcenter.nasdaq.com/IssuersPendingSuspensionDeli
SBFM
Truth and Transparency Truth and Transparency 15 minutes ago
Eh, Mark Smith partnered with the GXII scoundrels (Kehler/Bloom) and that didn’t work out too well. We have lost $300 million in market cap since that “partnership”. Mark has established that he doesn’t make good partnerships.

What were the tough questions that were raised to Mark du
NB
KOmani KOmani 16 minutes ago
This was posted to Triller:

(Removed broken link)

Hmmm it seems that the site doesn't allow a certain name to be posted....

https://greatawakening.win/p/17t1W3RIO6/djt-jr-promotes-triller-over-tik/c/
AGBA
Saving Grace Saving Grace 20 minutes ago
Massive Buy In. Insiders Buying Heavy

Nu Ride Inc. (NASDAQ:NRDE), previously known as Lordstown Motors (OTC:NRDE) Corp., has seen significant purchasing activity from one of its directors, Andrew L. Sole. According to recent filings, Sole has acquired a substantial number of shares v
NRDE
CanItBThisEZ2Make CanItBThisEZ2Make 23 minutes ago
BEST SELLERS RANK (BSR) IS 496 15 Estimated Sold on Amazon Since APRIL 1 - 2nd Quarter 2024

NOTE: In theory, when BSR Value Decreases Dongles are selling, when value Increases Dongles aren't selling!

BSR Relevance

Below 300 is OK (approximately 1 to 2 so
SRMX
BrandonSmith1 BrandonSmith1 24 minutes ago
I don't need to respond to your garbage with any comments.
AURI
PutzMueler PutzMueler 25 minutes ago
You mean 10,000 shares.eom


Not 1,000
NB
Doc logic Doc logic 26 minutes ago
dstock07734,

“…discovering IL-7 as the master regulator of T-cell homeostasis”. Now why would the master regulator of T-cell homeostasis have anything to do with the master immune cells of governed immune response (DCs). RevImmune with NWBO using Edens anyone?; ). Best wishes.
NWBO
ReasearchThis ReasearchThis 26 minutes ago
AXXA is a prime takeover company. AXXA is for all practical purposes a self sufficient company. Soon to be debt free. With
Literally millions in the bank get it!.
.
I heard AXXA has around 189 actual stock holders. If I count as one of them. Then at least a Hundred thousand sha
AXXA

Your Recent History

NASDAQ
CSTL
Castle Biosciences
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved